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Background:  Hypertrophic Cardiomyopathy (HCM) is associated with myocardial fibrosis. Our aim was to compare 2D Speckled Strain Testing 
(2D-STE) derived longitudinal strain values with quantified delayed enhancement (DE) above a designated normal myocardium.
Methods:  Of Patients who had DE on cardiac MRI (cMRI) and an Echocardiogram done within 90 days of one another, DE was manually quantified 
in 78 patients to date. The amount of DE was defined in amount of grams (g) at 2,3,4,5,6,8,10 Standard Deviations (SD) above a manually 
designated “normal” background on an average of 8 short-axis slices on cMRIs using Circle Cardiovascular Imaging 42 Software. This was then 
compared to Global Longitudinal (GLS), Basal, Apical, Anterior and Mid/Basal Strain values obtained using Echo-PAC software.
results:  Average age was 51.6 years (60% male). GLS, Mid and Basal strain values correlated well with DE 2, 3 and 4 SD above the designated 
normal myocardium as shown in the Spearman chart (table) on multivariate analysis. A GLS value of less than -13.2% had a sensitivity of 71% and 
a specificity of 80% to detect DE of 59g using the 2SD method. A Mid and Basal strain value of less than -13.92% had a sensitivity of 91.12% and 
specificity of 55% to detect 59 g of DE as quantified by the 2SD method.
conclusion:  Strain imaging offers a noninvasive method of estimating extent of delayed enhancement (and by extension- fibrosis) in patients with 
HCM
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